Navigation Links
Autism treatment is more than skin deep
Date:11/13/2012

Metal-binding agents rubbed into the skin, prescribed by some alternative practitioners for the treatment of autism, are not absorbed and therefore are unlikely to be effective at helping the body excrete excess mercury. The study by Jennifer Cohen and Michelle Ruha from Banner Good Samaritan Medical Center in the US, and their colleagues, provides evidence against the use of these treatments in children with autism. Their work is published online in Springer's Journal of Medical Toxicology.

Metal-binding agents such as DMPS* have received significant attention in recent decades amid the controversy over the link between mercury and autism. Even though no causal relationship between mercury in vaccines and autism has been proven, some practitioners treat their patients with mercury-binding agents in an effort to help the body eliminate mercury and treat the autism. One of these agents is a formulation of DMPS which is applied to the skin, also known as topical application. DMPS is approved in Europe for the treatment of heavy metal toxicity, but is not approved by the US FDA for use in the USA.

For the first time, Cohen and team looked at whether topically applied DMPS is absorbed into the body by measuring levels in the blood 30, 60, 90, 120, and 240 minutes after application. They also measured whether DMPS applied to the skin leads to increased excretion of mercury in the urine 12 and 24 hours after application. The study comprised eight healthy adult volunteers and one control subject who ingested oral DMPS, which is proven to increase mercury excretion.

None of the urine samples collected from the healthy subjects contained detectable DMPS at any time point. DMPS was also not detected in 40 of 41 blood samples, with a single sample found to have a small amount of DMPS, considered by the authors to be contamination of the sample. The control subject given oral DMPS had increased levels of DMPS in the blood at every time point and also detectable DMPS in the urine. In addition, topical application of DMPS did not lead to increased mercury excretion, whereas oral intake led to a six-fold increase.

Michelle Ruha concludes: "This is the first study of an expensive, non-FDA approved medication that is advertised on the internet and used on children to treat autism. Our results show that the drug is not absorbed and does not work as a metal-binding agent, when applied to the skin."


'/>"/>

Contact: Joan Robinson
joan.robinson@springer.com
49-622-148-78130
Springer
Source:Eurekalert

Related medicine news :

1. Study Explores Possible Tie Between Fever, Flu in Pregnancy and Autism
2. Link found between child prodigies and autism
3. Early treatment sparks striking brain changes in autism
4. Play-Focused Program Might Help Kids With Autism
5. Autism Tough to Spot Before 6 Months of Age, Study Suggests
6. At 6 months, development of children with autism like those without
7. Autism Speaks creates Delivering Scientific Innovation for Autism LLC
8. Drug Shows Promise Against Fragile X Syndrome, Possibly Autism
9. Children with autism experience interrelated health issues, says MU expert
10. Faculty from UCLA Center for Autism Research and Treatment receive multiple NIH awards
11. Almost Half of U.S. Kids With Autism Have Been Bullied
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... ... With the opioid epidemic now at the forefront, attention has shifted away from ... its misuse causes long-term consequences for all aspects of society, from the disastrous effects ... and older. In addition, there is the long term affects of chronic liver ...
(Date:5/3/2016)... Santa Monica, California (PRWEB) , ... May 03, 2016 , ... ... cosmetic surgery practice in late 2014, incorporating the injectable filler into his menu ... journeys of aesthetic transformation. Now, more than a year later, he’s still improving his ...
(Date:5/3/2016)... ... May 03, 2016 , ... Diagnotes, ... by Tidelands Health, a three hospital system in South Carolina, to provide its ... lookout for technology that enhances communication, drives workflow efficiencies and improves provider and ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Park Cities ... live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, ... Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas ...
(Date:5/3/2016)... Corner, VA (PRWEB) , ... May 03, 2016 ... ... leading provider of innovative information technology (IT) solutions and digital consulting services to ... Enterprise Information Technology Services (EITS) Indefinite Delivery / Indefinite Quantity (ID/IQ) contract in ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... YORK , May 2, 2016  Deerfield ... B financing of Graybug Vision, Inc. Graybug Vision ... developing therapies that may transform care for ocular ... glaucoma.  Graybug Vision,s technology was first developed at ... into a startup venture. Graybug ...
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
Breaking Medicine Technology: